Reducing Blood Cancer Patients' Need for Transfusions
January 21, 2020—(BRONX, NY)—A clinical trial has found the drug luspatercept significantly reduced the need for blood transfusions in people with lower-risk myelodysplastic syndromes (MDS), a group of bone marrow disorders that leave people with many defective blood cells and too few normal ones. Approval by the Food and Drug Administration (FDA) would make luspatercept the first new drug available to MDS patients in 12 years.Results of the phase 3 clinical trial were published online January 9 in the New England Journal of Medicine (NEJM).
Source: Einstein News - Category: Universities & Medical Training Source Type: news
Related Links:
Effects of acute and chronic graft-versus-myelodysplastic syndrome on long-term outcomes following a
(The Institute of Medical Science, The University of Tokyo) A research group led by Assistant Professor Takaaki Konuma in the Department of Hematology/Oncology, the Hospital of the Institute of Medical Science, the University of Tokyo (IMSUT Hospital) has demonstrated a graft-versus-tumor (GVT) effect of a previously unknown/novel allogeneic hematopoietic cell transplantation in MDS patients. In addition, they succeeded in identifying a category of patients for whom the GVT effect was identified.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Blood Cancer Journal, Published online: 06 October 2020; doi:10.1038/s41408-020-00362-7FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome
Source: Blood Cancer Journal - Category: Hematology Authors: Michael Schieber Christian Marinaccio Lyndsey C. Bolanos Wendy D. Haffey Kenneth D. Greis Daniel T. Starczynowski John D. Crispino Source Type: research
AbstractBackground Patients with haematological malignancies are at high risk of invasive fungal infections. However, there is a lack of information about the utilisation of the recommended Australian antifungal prophylaxis guidelines in haematology outpatients.Objective To assess the impact of a weekly pharmacist review of high-risk adult haematology outpatients on the utilisation of appropriate antifungal prophylaxis.Setting Outpatient cancer centre, tertiary referral hospital in Sydney, Australia.Method A 3-month pre-and post-interventional study was conducted. A retrospective audit was conducted to obtain baseline util...
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
Authors: Liu L, Liu X, Sun Y, Zeng Y, Tang X, Li X, Liu J, Xiao R
Abstract
Esophageal squamous cell carcinoma (ESCC) is one of the most common malignant tumors, and has high incidence and mortality rates, worldwide. Myelodysplastic syndrome (MDS), a disorder of hematopoietic stem or progenitor cells, results in marrow failure, which increases the risk of acute myeloid leukemia (AML). Few studies had reported patients who have suffered from both ESCC and MDS/AML simultaneously. To identify possible potential associations between ESCC and MDS/AML, the present case report describes a patient with both types of these t...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Volume 9, Issue 1, January 2020 .
Source: OncoImmunology - Category: Cancer & Oncology Authors: Ana Mar ía Hurtado López Tzu Hua Chen-Liang Mar ía Zurdo Salvador Carrillo-Tornel Joaqu ín Panadero Eduardo Jos é Salido Victor Beltr án Bego ña Muiña MariLuz Amigo Noelia Navarro-Villamor Rosa Cifuentes In és Calabria Ana Isabel Ant ón Ra úl T Source Type: research
We present long-term safety data for niraparib from the ENGOT-OV16/NOVA trial.
METHODS: This multicenter, double-blind, randomized, controlled phase III trial evaluated the efficacy and safety of niraparib for the treatment of recurrent ovarian cancer. Patients were randomly assigned 2:1 to receive either once-daily niraparib 300 mg or placebo. Two independent cohorts were enrolled based on germline BRCA mutation status. The primary endpoint was progression-free survival, reported previously. Long-term safety data were from the most recent data cutoff (September 2017).
RESULTS: Overall, 367 patients received...
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Mirza MR, Benigno B, Dørum A, Mahner S, Bessette P, Barceló IB, Berton-Rigaud D, Ledermann JA, Rimel BJ, Herrstedt J, Lau S, du Bois A, Herráez AC, Kalbacher E, Buscema J, Lorusso D, Vergote I, Levy T, Wang P, de Jong FA, Gupta D, Matulonis UA Tags: Gynecol Oncol Source Type: research
Conclusions: we identified specific lncRNAs contributing to MDS pathogenesis and proposed cellular processes associated with these transcripts. Of the lncRNAs associated with patient prognosis, the level of H19 transcript might serve as a robust marker comparable to the clinical variables currently used for patient stratification.
Source: Cancers - Category: Cancer & Oncology Authors: Katarina Szikszai Zdenek Krejcik Jiri Klema Nikoleta Loudova Andrea Hrustincova Monika Belickova Monika Hruba Jitka Vesela Viktor Stranecky David Kundrat Pavla Pecherkova Jaroslav Cermak Anna Jonasova Michaela Dostalova Merkerova Tags: Article Source Type: research
Abstract
We retrospectively analyzed nationwide records of 163 Fanconi anemia (FA) patients [aplastic anemia (AA), n = 118; myelodysplastic syndrome (MDS), n = 30; acute leukemia, n = 15] who underwent first allogeneic hematopoietic stem cell transplantation (HSCT) between 1987 and 2015 in Japan. An alternative donor was used in 119 (73%) patients, and 160 (98%) patients received a non-T-cell-depleted graft. With an 8.7-year median follow-up, 5-year overall survival (OS) was 81%. The 5-year OS was significantly higher in AA patients than in MDS and acute leukemia patients ...
Source: International Journal of Hematology - Category: Hematology Authors: Yabe M, Morio T, Tabuchi K, Tomizawa D, Hasegawa D, Ishida H, Yoshida N, Koike T, Takahashi Y, Koh K, Okamoto Y, Sano H, Kato K, Kanda Y, Goto H, Takita J, Miyamura T, Noguchi M, Kato K, Hashii Y, Astuta Y, Yabe H Tags: Int J Hematol Source Type: research
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announce a strategic collaboration agreement aimed at accelerating the clinical evaluation of Astex's pipeline of products for patients with certain types of leukemia, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). The collaboration will combine MD Anderson's clinical trials infrastructure and expertise with Astex's clinical pipeline products.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
CONCLUSIONS: These data demonstrated a survival benefit of the graft-versus-MDS effect is present only in high-risk MDS patients with limited chronic GVHD.
PMID: 32895232 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Konuma T, Ishiyama K, Igarashi A, Uchida N, Ozawa Y, Fukuda T, Ueda Y, Matsuoka KI, Mori T, Katayama Y, Onizuka M, Ichinohe T, Atsuta Y Tags: Clin Cancer Res Source Type: research
